Energy status, ubiquitin proteasomal function, and oxidative stress during chronic and acute complex I inhibition with rotenone in mesencephalic cultures

Antioxidants and Redox Signaling

Volumn 7, Issue 5-6, 2005, Pages 662-672

  Zeevalk, Gail D ^a   Bernard, Laura P ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CHYMOTRYPSIN; DOPAMINE; FREE RADICAL; GLUCOSE; LACTIC ACID; NEURON SPECIFIC ENOLASE; PROTEASOME; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; TYROSINE 3 MONOOXYGENASE; UBIQUITIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; ENERGY; ENZYME ACTIVATION; ENZYME INHIBITION; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MESENCEPHALON; MITOCHONDRIAL RESPIRATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; UBIQUITINATION; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DOPAMINE; ELECTRON TRANSPORT COMPLEX I; ENERGY METABOLISM; GAMMA-AMINOBUTYRIC ACID; GLUCOSE; MESENCEPHALON; MOLECULAR WEIGHT; OXIDATIVE STRESS; PHOSPHOPYRUVATE HYDRATASE; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; REACTIVE OXYGEN SPECIES; ROTENONE; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; UBIQUITIN;

EID: 17644411438     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.662     Document Type: Article

References (55)

1. Barrientos A and Moraes CT. Titrating the effects of mitochondrial complex 1 impairment in the cell physiology. J Biol Chem 274: 16188-16197, 1999.
2. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, and Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306, 2000.
3. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259, 2003.
4. Bywood PT and Johnson SM. Mitochondrial complex inhibitors preferentially damage substantia nigra dopamine neurons in rat brain slices. Exp Neurol 179: 47-59, 2002.
5. Ciechanover A, Heller H, Elias S, Haas AL, and Hershko A. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc Natl Acad Sci USA 77: 1365-1368, 1980.
6. Ciechanover A, Finley D, and Varshavsky A. Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85. Cell 37: 57-66, 1984.
7. Davey GP, Peuchen S, and Clark JB. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J Biol Chem 273: 12753-12757, 1998.
8. Drewes L, Gilboe DD, and Betz LA. Metabolic alterations in brain during anoxic-anoxia and subsequent recovery. Arch Neurol 29: 385-390, 1973.
9. Driscoll BF, Deibler GE, Law MJ, and Crane AM. Damage to neurons in culture following medium change: role of glutamine and extracellular generation of glutamate. J Neurochem 61: 1795-1800, 1993.
10. Ehrhart J and Zeevalk GD. Hydrogen peroxide removal and glutathione mixed disulfide formation during metabolic inhibition in mesencephalic cultures. J Neurochem 77: 1496-1507, 2001.
11. Fellows LK, Boutelle MG, and Fillenze M. Physiological stimulation increases nonoxidative glucose metabolism in the brain of the freely moving rat. J Neurochem 60: 1258-1263, 1993.
12. Forno LS, DeLanney IE, Irwin I, and Langston JW. Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Adv Neurol 69: 217-228, 1996.
13. Fox PT, Raichle ME, Mintun MA, and Dence C. Non-oxidative glucose consumption during focal physiologic neural activity. Science 241: 462-464, 1988.
14. Gao H-M, Hong J-S, Zhang W, and Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22: 782-790, 2002.
15. Grune T, Reinheckel T, and Davies KJA. Degradation of oxidized proteins in mammalian cells. FASEB J 11: 526-534, 1997.
16. Haas RH, Nasirian F, Nakano K, Ward D, Pay RN, Hill R, and Shults CW. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37: 714-722, 1995.
17. Heikkila RE, Hess A, and Duvoisin RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224: 1451-1453, 1984.
18. Hensley K, Pye QN, Maidt ML, Stewart CA, Robinson KA, Jaffrey F, and Floyd RA. Interaction of alpha-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site. J Neurochem 71: 2549-2557, 1998.
19. Hershko A, Ciechanover A, Heller H, Haas AL, and Rose IA. Proposed role of ATP in protein breakdown: conjugation of proteins with miltiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci USA 77: 1783-1786, 1980.
20. Hoglinger GU, Feger J, Prigent A, Michel PP, Parain K, Champy P, Ruberg M, Oertel WH, and Hirsch EC. Chronic systemic complex 1 inhibition induces a hypokinetic multi-system degeneration in rats. J Neurochem 84: 491-502, 2003.
21. Keller JN, Huang FF, Dimayuga ER, and Maragos WF. Dopamine induces proteasome inhibition in a neuronal PC12 cell line. Free Radic Biol Med 29: 1037-1042, 2000.
22. Langston JW, Ballard PA, Tetrud JW, and Irwin I. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 219: 979-980, 1983.
23. Langsten JW, Forno LS, Rebert CS, and Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 292: 390-394, 1984.
24. LeCouteur DG, McLean AJ, Taylor MC, Woodham BL, and Board PG. Pesticides and Parkinson's disease. Biomed Pharmacother 53: 122-130, 1999.
25. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein M, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach P, Wilkinson K, and Polymeropoulos M. The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452, 1998.
26. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, and Robinson JP. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278: 8516-8525, 2003.
27. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ. Protein measurement with the Polin phenol reagent. J Biol Chem 193: 265-275, 1951.
28. Manaye KF, Sonsalla PK, Barnett G, Heikkila RE, Woodward DJ, Smith WK, and German DC. 1-Methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine (2′CH3-MPTP)-induced degeneration of mesostriatal dopaminergic neurons in the mouse: biochemical and neuroanatomical studies. Brain Res 491: 307-315, 1989.
29. Marey-Semper I, Gelman M, and Levi-Strauss ML. The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra. Eur J Neurosci 5: 1029-1034, 1993.
30. Marey-Semper I, Gelman M, and Levi-Strauss M. A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation. J Neurosci 15: 5912-5918, 1995.
31. McNaught KS and Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 297: 191-194, 2001.
32. Mizuno Y, Matsuda S, Yoshino H, Mori H, Hattori N, and Ikebe SI. An immunohistochemical study on αketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 35: 204-210, 1994.
33. Mouradain MM. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58: 179-185, 2002.
34. Moy LY, Zeevalk GD, and Sonsalla PK. Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures. J Neurochem 74: 1656-1665, 2000.
35. Nicholls DG and Ferguson SJ. Bioenergetics 2. London and San Diego: Academic Press, 1992.
36. Nicklas WJ, Vyas I, and Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36: 2503-2508, 1985.
37. Pacifici RE, Salo DC, and Davies KJA. Macroxyproteinase (MPO): a 670 kDa proteinase complex that degrades oxidatively denatured proteins in red blood cells. Free Radic Biol Med 7: 521-536, 1989.
38. Parker WD, Boyson SJ, and Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719-733, 1989.
39. Rehncrona S, Rosen I, and Siesjo BK. Brain lactic acidosis and ischemic cell damage. J Cereb Blood Flow Metab 1: 297-311, 1981.
40. Rideout HJ, Larsen KE, Sulzer D, and Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 78: 899-908, 2001.
41. Ritz B and Yu F. Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int J Epidemiol 29: 323-329, 2000.
42. Salo DC, Pacifici RE, and Davies KJA. Superoxide dismutase undergoes proteolysis and fragmentation following oxidative modification and inactivation. J Biol Chem 265: 11919-11927, 1990.
43. 31P magnetic resonance spectroscopy. J Cereb Blood Flow Metab 12:584-592, 1992.
44. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, and Marsden CD. Mitochondrial complex 1 deficiency in Parkinson's disease. Lancet 1: 1269, 1989.
45. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, and Greenamyre JT. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22: 7006-7015, 2002.
46. Sherer TB, Kim J-H, Betarbet R, and Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179: 9-16, 2003.
47. Shimur H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, and Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25: 302-305, 2000.
48. Shults CW, Haas RH, Passov D, and Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and 11/111 in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 42: 261-264, 1997.
49. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, and Greene LA. Expression of A53T mutant but not wild-type alpha-synuclein in PC 12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 21: 9549-9560, 2001.
50. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, and Langston JW. Parkinson disease in twins: an etiologic study. JAMA 281: 341-346, 1999.
51. Trojanowski JQ and Lee VMY. Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses. Neurotoxicology 23: 457-460, 2002.
52. Varshavsky A. The ubiquitin system. Trends Biochem Sci 22: 383-387, 1997.
53. Winkler BS. Glycolytic and oxidative metabolism in relation to retinal function. J Gen Physiol 77: 667-692, 1981.
54. Zeevalk GD and Nicklas WJ. Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina. J Pharmacol Exp Ther 253: 1285-1292, 1990.
55. Zeevalk GD, Bernard LP, Manzino L, and Sonsalla PK. Differential sensitivity of mesencephalic neurons to inhibition of phosphatase 2A. J Pharmacol Exp Ther 298: 925-933, 2001.